BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15449303)

  • 1. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis.
    Livingston G; Katona C
    Int J Geriatr Psychiatry; 2004 Oct; 19(10):919-25. PubMed ID: 15449303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R
    Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine for treatment of moderate to severe Alzheimer's disease.
    Perras C
    Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
    Feldman HH; Schmitt FA; Olin JT;
    Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
    Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
    Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
    Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
    Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine for dementia?
    Drug Ther Bull; 2003 Oct; 41(10):73-6. PubMed ID: 14593973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
    Gauthier S; Loft H; Cummings J
    Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
    Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
    Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies.
    Gauthier S; Wirth Y; Möbius HJ
    Int J Geriatr Psychiatry; 2005 May; 20(5):459-64. PubMed ID: 15852444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
    Jones RW; Bayer A; Inglis F; Barker A; Phul R
    Int J Geriatr Psychiatry; 2007 Mar; 22(3):258-62. PubMed ID: 17243195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.
    Grossberg GT; Pejović V; Miller ML; Graham SM
    Dement Geriatr Cogn Disord; 2009; 27(2):164-72. PubMed ID: 19194105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The action of memantine on the cognitive disorders of patients with dementia: reflections following two years' experience in Spain].
    Robles-Bayón A
    Rev Neurol; 2006 Mar 1-15; 42(5):288-96. PubMed ID: 16538592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advanced dementia in Alzheimer's disease and memantine].
    Alberca R
    Rev Neurol; 2005 Feb 1-15; 40(3):173-9. PubMed ID: 15750904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.